SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a broad crypto selloff linked to the reported record-scale Binance hack, which has stirred concerns about exchange security and possible further selling. Traders are divided between viewing the dip as a buying opportunity and warning that trust concerns and market weakness could bring more downside.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs scheduled quarterly report is the main focus, with traders debating whether guidance can justify its high valuation amid a broader pullback in AI stocks. Bulls expect continued AI-driven growth, while bears argue that even an earnings beat may disappoint if the outlook does not exceed already high expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios accelerated FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and triggered a sharp selloff. Traders debate the threat: some emphasize Inovios potential to reduce surgeries, while others point to Precigens first-mover commercial lead and full approval, alongside questions about the rivals launch and reimbursement path.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORUs sharp decline is drawing attention as South Korean stocks, particularly semiconductor shares, sell off amid concerns about AI demand and chip competition. Traders are divided between buying what they see as an oversold dip and warning that further losses and leverage-driven volatility could deepen the drop.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of Marvells possible acquisition of Lumentum are driving attention, with traders focused on potential financing, shareholder dilution, and execution risks. Some see the deal as a strategic way to secure optical components for AI data centers, while others view the selloff as justified or an opportunity to buy the dip; the talks remain unconfirmed.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders viewing the report as evidence of improving performance. The community is debating whether the pullback reflects profit-taking and broader market weakness or whether heavy short interest could fuel further gains; squeeze claims remain speculation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks stronger-than-expected third-quarter results and raised full-year outlook are drawing attention, with traders also highlighting a bullish flag pattern and a potential breakout. Some discussion continues around the melanoma cancer-vaccine partnership with Moderna, but views differ on how much commercial value the trial results may add.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

ANET is drawing attention after a sharp pullback from recent highs, with traders pointing to selling pressure and technical weakness ahead of the next earnings report; some also cite bearish options flow and insider sales, though these are not established as the cause. The community is split between treating the decline as a buying opportunity based on Aristas AI data-center networking demand and cash-rich balance sheet, and waiting for further downside or support to form.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharply weaker-than-expected outlook after its quarterly reportamid soft PC demand and supply constraintstriggered a historic selloff and renewed concerns about its recovery and exposure to the AI trade. Traders are split between calling the drop an overreaction and buying the dip, and warning that further losses may follow.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a broader semiconductor selloff as investors question whether massive AI infrastructure spending will earn adequate returns, with some traders calling the financing circular. Bulls point to Broadcoms role supplying AI chips and Anthropics large financing and equipment commitments, while others worry about the guarantees and dependence on continued customer spending.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics

Besides Wall Street's top-and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why McKesson (MCK) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why McKesson (MCK) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's How Much $100 Invested In McKesson 5 Years Ago Would Be Worth Today

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 25.96% on an annualized basis producing an average annual return of 36.71%. Currently, McKesson has a market capitalization of $118.03 billion.read more...

McKesson (MCK) Stock Dips While Market Gains: Key Facts

The latest trading day saw McKesson (MCK) settling at $1, representing a -1.42% change from its previous close.

Is Trending Stock McKesson Corporation (MCK) a Buy Now?

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

McKesson Corporation Declares Quarterly Dividend

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026. About McKesson Corporation McKesson Corporation is a diversified...

McKesson (MCK) Outperforms Broader Market: What You Need to Know

In the latest trading session, McKesson (MCK) closed at $1, marking a +1.95% move from the previous day.

McKesson Corp. engages in providing healthcare services. It operates through the following segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. The North American Pharmaceutical segment focuses on distribution of branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs to customers in U.S. and Canada. The Oncology and Multispecialty segment includes provision of solutions that includes specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, InspiroGene cell and gene therapy services, technology solutions, practice consulting services, and vaccine distribution. The RxTS segment focuses on solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Mckesson Corporation

OPCH Stock Soars 22% After-Hours On $5B McKesson Buyout Talks

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>A deal could be reached as soon as Tuesday, though nothing is signed and the talks could still collapse, FT added.&nbsp;</li><li>Under the terms being discussed, CD&amp;R would own 51% through a joint venture and McKesson 49%, with McKesson holding a right to buy the buyout firm’s stake later, the paper said.</li><li>The bid lands after a soft stretch for Option Care: in late July, the company narrowed full-year guidance to $5.675 billion to $5.775 billion of revenue and adjusted earnings of $1.85 to $1.92 a share.</li></ul><p>Option Care Health (OPCH) shares jumped about 22% in after-hours trading on Monday after a report that McKesson (MCK) and private equity firm Clayton Dubilier &amp; Rice are closing in on a buyout worth more than $5 billion, including debt.</p><p><a class="mention" data-mention="$OPCH" data-symbol-id="OPCH" href="https://stocktwits.com/symbol/OPCH" target="_blank">OPCH shares</a> closed up 3% on Monday, giving the company a market capitalization of about $3.5 billion. Including debt, the company has an enterprise value of $4.7 billion.</p><p>Healthcare firm McKesson, in comparison, has a market value of about $107 billion.</p><h2 class="st-heading-2">OPCH-MCK Talks Not Yet Signed</h2><p>Option Care, the largest independent U.S. provider of medical infusion services, is in advanced talks after a joint bid, people familiar with the matter told the Financial Times. A deal could be reached as soon as Tuesday, though nothing is signed and the talks could still collapse, it added.</p><p>Under the terms being discussed, CD&amp;R would own 51% through a joint venture and McKesson 49%, with McKesson holding a right to buy the buyout firm’s stake later, the paper said.</p><h2 class="st-heading-2">A Fit With Oncology And Home Care</h2><p>Option Care last year treated more than 315,000 patients who need specialty drugs by infusion for cancer, autoimmune disease and serious infections, either at home or at 184 centers. Hospital infusion is expensive, and more complex biologic drugs can only be given that way, which has supported the business.</p><p>For McKesson, the network would sit alongside its drug-distribution core and its chemotherapy and cancer-care clinics, one of the faster-growing parts of a company with about $403 billion in annual revenue. In August, McKesson agreed to buy Precision Medicine Group for about $2.25 billion to deepen clinical research and commercialization services.</p><p>The bid lands after a soft stretch for Option Care. In late July, the company reported second-quarter revenue of $1.44 billion, up 1.9% from a year earlier, and narrowed full-year guidance to $5.675 billion to $5.775 billion of revenue and adjusted earnings of $1.85 to $1.92 a share. Management said one long-running therapy weighed on results, even as short-term infusions and some rare-disease treatments held steady.</p><h2 class="st-heading-2">How Did OPCH, MCK Retail Traders React?</h2><p>On Stocktwits, retail sentiment around OPCH stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p>Meanwhile, sentiment around MCK stayed within ‘neutral’ levels.</p><p>While OPCH has lost 27% year-to-date, MCK has gained 12%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-ends-higher-on-starship-fuel-plans-analyst-optimism-and-tsmc-talks/cZDqBUNRBjY">SPCX Stock Ends Higher On Starship Fuel Plans, Analyst Optimism And TSMC Talks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Option Care is in advanced talks after a joint bid from McKesson and private equity firm Clayton Dubilier & Rice, FT reported. 

Option Care Health Inc. - Registered Shares

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$994.58
Prev Close	$980.88
Open	$1,006.29
Dividend Yield	0.37%
50-Day Moving Average	$922.19
Beta	0.01
Avg. Volume	860,873.67
PE Ratio	26.61

52-Week High	$1,030.27
52-Week Low	$723.68
Market Capitalization	$115.96B
EPS (Annual)	$38.37
Price to Book	-27.21
Revenue Per Employee	$9.38M

Feed

News

Sentiment

Earnings

Fundamentals

Info

MCK Fundamentals